Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/DIS3L2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/DIS3L2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/DIS3L2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/DIS3L2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/DIS3L2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/DIS3L2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004348823 | Oral cavity | EOLP | regulation of mRNA stability | 50/2218 | 158/18723 | 2.91e-11 | 4.15e-09 | 50 |
GO:004348723 | Oral cavity | EOLP | regulation of RNA stability | 51/2218 | 170/18723 | 1.63e-10 | 1.68e-08 | 51 |
GO:190331323 | Oral cavity | EOLP | positive regulation of mRNA metabolic process | 40/2218 | 118/18723 | 2.69e-10 | 2.45e-08 | 40 |
GO:003465523 | Oral cavity | EOLP | nucleobase-containing compound catabolic process | 89/2218 | 407/18723 | 5.47e-09 | 2.92e-07 | 89 |
GO:004670023 | Oral cavity | EOLP | heterocycle catabolic process | 93/2218 | 445/18723 | 2.61e-08 | 1.08e-06 | 93 |
GO:001982713 | Oral cavity | EOLP | stem cell population maintenance | 38/2218 | 131/18723 | 9.10e-08 | 3.15e-06 | 38 |
GO:004427023 | Oral cavity | EOLP | cellular nitrogen compound catabolic process | 92/2218 | 451/18723 | 1.01e-07 | 3.45e-06 | 92 |
GO:009872713 | Oral cavity | EOLP | maintenance of cell number | 38/2218 | 134/18723 | 1.74e-07 | 5.61e-06 | 38 |
GO:000095623 | Oral cavity | EOLP | nuclear-transcribed mRNA catabolic process | 33/2218 | 112/18723 | 4.21e-07 | 1.19e-05 | 33 |
GO:006101423 | Oral cavity | EOLP | positive regulation of mRNA catabolic process | 28/2218 | 87/18723 | 4.26e-07 | 1.19e-05 | 28 |
GO:001943923 | Oral cavity | EOLP | aromatic compound catabolic process | 92/2218 | 467/18723 | 5.23e-07 | 1.40e-05 | 92 |
GO:190136123 | Oral cavity | EOLP | organic cyclic compound catabolic process | 95/2218 | 495/18723 | 1.15e-06 | 2.80e-05 | 95 |
GO:005077915 | Oral cavity | EOLP | RNA destabilization | 27/2218 | 88/18723 | 1.95e-06 | 4.47e-05 | 27 |
GO:006115715 | Oral cavity | EOLP | mRNA destabilization | 26/2218 | 84/18723 | 2.50e-06 | 5.54e-05 | 26 |
GO:001714813 | Oral cavity | EOLP | negative regulation of translation | 54/2218 | 245/18723 | 4.15e-06 | 8.72e-05 | 54 |
GO:003424913 | Oral cavity | EOLP | negative regulation of cellular amide metabolic process | 58/2218 | 273/18723 | 6.23e-06 | 1.22e-04 | 58 |
GO:00008192 | Oral cavity | EOLP | sister chromatid segregation | 36/2218 | 202/18723 | 7.92e-03 | 3.76e-02 | 36 |
GO:00105866 | Oral cavity | EOLP | miRNA metabolic process | 8/2218 | 27/18723 | 1.07e-02 | 4.75e-02 | 8 |
GO:0009896113 | Thyroid | PTC | positive regulation of catabolic process | 278/5968 | 492/18723 | 3.35e-30 | 2.64e-27 | 278 |
GO:0031331113 | Thyroid | PTC | positive regulation of cellular catabolic process | 249/5968 | 427/18723 | 5.28e-30 | 3.58e-27 | 249 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DIS3L2 | SNV | Missense_Mutation | rs376340398 | c.1459N>T | p.Arg487Cys | p.R487C | Q8IYB7 | protein_coding | tolerated(0.14) | benign(0.224) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
DIS3L2 | SNV | Missense_Mutation | novel | c.478N>A | p.Asp160Asn | p.D160N | Q8IYB7 | protein_coding | tolerated(0.4) | benign(0.071) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
DIS3L2 | SNV | Missense_Mutation | novel | c.665N>C | p.Arg222Thr | p.R222T | Q8IYB7 | protein_coding | tolerated(0.49) | benign(0.003) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
DIS3L2 | SNV | Missense_Mutation | novel | c.2366A>G | p.Tyr789Cys | p.Y789C | Q8IYB7 | protein_coding | deleterious(0) | benign(0.073) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DIS3L2 | SNV | Missense_Mutation | rs770702636 | c.1693N>A | p.Gly565Arg | p.G565R | Q8IYB7 | protein_coding | deleterious(0.01) | benign(0.427) | TCGA-D8-A27N-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxol+adriamycin+cyclophosphamide+herceptin | SD |
DIS3L2 | SNV | Missense_Mutation | novel | c.983A>G | p.Glu328Gly | p.E328G | Q8IYB7 | protein_coding | deleterious(0) | possibly_damaging(0.696) | TCGA-EW-A1IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | aromasin | SD |
DIS3L2 | SNV | Missense_Mutation | novel | c.2376N>C | p.Gln792His | p.Q792H | Q8IYB7 | protein_coding | deleterious(0.03) | benign(0) | TCGA-C5-A7X8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
DIS3L2 | SNV | Missense_Mutation | novel | c.1417G>A | p.Glu473Lys | p.E473K | Q8IYB7 | protein_coding | tolerated(0.14) | benign(0.007) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
DIS3L2 | SNV | Missense_Mutation | novel | c.821G>A | p.Arg274Gln | p.R274Q | Q8IYB7 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DIS3L2 | SNV | Missense_Mutation | rs368280072 | c.2381N>A | p.Arg794His | p.R794H | Q8IYB7 | protein_coding | deleterious(0) | benign(0.356) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |